No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

Sinan Batman Appointed CTO of TeraRecon

Editor: What To Know

  • Earlier In his career, Sinan Batman has developed computer-aided diagnosis algorithms for breast cancer detection and was one of the early scientists working on quantifying gene expression using microarray imaging technologies for the US National Institutes of Health.
  • Batman modeled, simulated, and optimized quantum-well laser diodes and arrays while working as a Research Scientist at Xerox Research Labs in a NASA-sponsored project.
  • TeraRecon understands that and is leading the enterprise AI movement in healthcare as a result.

Sinan Batman will be responsible for developing next-gen, AI-based advanced visualization and clinical workflow application technologies.

“Sinan shares our drive for better patient outcomes and value through out-of-the-box solutions for streamlined efficiency and effectiveness,” said Romesh Wadhwani, chairman and founder of parent company SymphonyAI. “He brings a track record of delivering value to customers by building and deploying innovative solutions that make analytics and decision support simple, ubiquitous, and transparent.”

Sinan Batman brings rich industry experience to TeraRecon, including Chief Engineer at Carestream/Kodak Health Group, where he defined the vision for image-centric workflow information systems. At Fujifilm Medical Systems USA, he was Executive Technical Director of Research and Development, heading the core medical IT product development and leading 200 product releases. Batman directed the Digital Innovation and Data Science Teams at Hillrom, leading the development of class-leading health risk prediction algorithms across the care continuum.

Earlier In his career, Sinan Batman has developed computer-aided diagnosis algorithms for breast cancer detection and was one of the early scientists working on quantifying gene expression using microarray imaging technologies for the US National Institutes of Health. He developed advanced autonomous medical imaging algorithms for disease and target detection as a research scientist at Johns Hopkins University. Batman modeled, simulated, and optimized quantum-well laser diodes and arrays while working as a Research Scientist at Xerox Research Labs in a NASA-sponsored project.

“Time-to-value is an essential ingredient for product and technology success,” said Batman. “It takes more than sophisticated tools, like a high-quality AI platform, though that is a necessity. Success comes from the hard work of developing real solutions that business enterprises can see value from immediately. Solutions must use a nuanced understanding of how healthcare works. TeraRecon understands that and is leading the enterprise AI movement in healthcare as a result.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy